Charlotte-Paige Rolle

Also affiliated with Orlando Immunology Center, Rollins College

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial”.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Nature Medicine(2022)10.1038/s41591-022-01815-1

N/A

2.7DataRank · unranked

143 citations

Kathryn E. Stephenson, Kshitij Wagh, Sabrina C. Tan, Rebecca Zash, Stephen R. Walsh +32 more

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Nature Medicine(2021)10.1038/s41591-021-01509-0

N/A

2.3DataRank · unranked

104 citations

Boris Jülg, Chen Sabrina Tan, Rebecca Zash, Stephen R. Walsh, Charlotte-Paige Rolle +35 more

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial

The Journal of Infectious Diseases(2020)10.1093/infdis/jiaa259

N/A

0.466DataRank · unranked

13 citations

Heather J. Ribaudo, Jorge Leon-Cruz, Edgar T. Overton, Markella V. Zanni, Carlos Malvestutto +89 more

From declining PrEP to PrEP initiation as “first nature” – what changes PrEP initiation decisions among young, Black MSM

AIDS Care(2021)10.1080/09540121.2021.1960946

N/A

0DataRank · unranked

20 citations

Annie Lockard, Colleen F. Kelley, David P. Serota, Charlotte-Paige Rolle, Patrick S. Sullivan +3 more

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Open Forum Infectious Diseases(2023)10.1093/ofid/ofad101

N/A

0DataRank · unranked

24 citations

Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal +12 more